Psoriasis (PSO) is a common skin disease that affects about 1%–3% of the general population. It is a great medical, social and economic burden since PSO is associated with many comorbidities, of which the most common are cardiometabolic disorders. Psoriatic patients suffer more frequently from obesity, dyslipidemia, atherosclerosis, and nonalcoholic fatty liver disease. Research shows that lipid expression and metabolism disorders are present more often in such patients. This review focuses on a variety of aberrations in lipids in the skin, blood, and adipose tissue in psoriatic patients and their multifactorial impact on the pathogenesis of psoriasis.

Psoriasis is a chronic, inflammatory skin disease affecting 2–4% of the general population. Accompanying subjective symptoms (pruritus or pain) may cause decreased life quality including sleep disorders (SD). Sixty psoriatic patients fulfilled the following questionnaires: Pittsburgh Sleep Quality Index (PSQI), STOP BANG for the obstructive sleep apnea syndrome (OSAS) assessment, and Restless Legs Syndrome (RLS) Severity Scale. Patients’ laboratory and clinical data were also investigated. All data obtained were compared to 40 participants without dermatoses. Mean PSQI, risk of OSAS, and RLS severity of psoriatics were significantly higher than in controls (p < 0.0001, p < 0.05, p < 0.05 respectively). There was a positive correlation between the time of suffering from psoriasis and the risk of OSAS (R = 0.286, p < 0.05). We did not observe any significant relationship between PSQI, risk of OSAS, or RLS and psoriasis severity assessed with PASI (Psoriasis Area and Severity Index). We identified four possible predictors of RLS: glucose, CRP and total cholesterol concentrations, and PSQI. SD are significantly more frequent in psoriatics than in people without chronic dermatological diseases but surprisingly they are not correlated with psoriasis severity. SD decrease patients’ life quality and may result in serious consequences. Therefore, establishing recommendations concerning screening for SD and their predictors should be considered.

Psoriasis is a chronic, autoimmune skin disease affecting about 2–4% of the worldwide population. It is now perceived as a systemic disease because of the complex pathogenesis and multiple comorbidities. It leads to decreased quality of life and productivity of patients. Nowadays, sleep disorders are investigated as well in relation to psoriasis as another possible comorbidity. This review focuses on possible negative effects of sleep deprivation, decreased quality of life, and psychosocial status in patients with psoriasis and highlights their mutual, complex relationship of divergent consequences. The relationship between sleep disorders and psychosocial status in patients with psoriasis is bidirectional and resembles a vicious circle, one abnormality triggering the other. Sleep disorders additionally increase the risk of metabolic and psychiatric diseases in psoriatic patients who are already at increased risk of developing such disorders. There should be measures taken to screen patients with psoriasis for sleep disorders in order to diagnose early and treat.

Introduction: Psoriasis is a chronic, autoimmune, inflammatory skin disease affecting 2-4% of the general population, which nowadays is even perceived as a systemic illness. The nature of this dermatosis may negatively influence patients' general condition, life

Psoriasis is a chronic, inflammatory, autoimmune skin disease affecting 2-4% of general population. It is an important social issue, because of its confirmed associations with metabolic syndrome. Individals with psoriasis are at an increased risk of developing cardiovascular disorders and diabetes mellitus. Psoriasis and its comorbidities have multiple common pathogenic pathways including the chronic inflammatory process, immunological abnormalities, genetic links and different bioactive proteins secreted by the adipose tissue. Considering the above associations, it is advisable to perform screening tests in patients with psoriasis to detect metabolic disorders as they not only increase mortality in these individuals, but also decrease their life quality significantly. An essential issue is also the education and the improvement of doctor-patient relationship, as well as early introducing of preventive measures. streszczenie Łuszczyca jest przewlekłą, zapalną, autoimmunologiczną chorobą skóry dotyczącą 2-4% populacji. Stanowi istotny problem społeczny ze względu na związek z zespołem metabolicznym, co zwiększa ryzyko zachorowania na choroby układu sercowo-naczyniowego i cukrzycę. Łuszczyca i choroby z nią współistniejące mają wiele wspólnych szlaków patogenetycznych, m.in. przewlekły proces zapalny, zaburzenia immunologiczne, czynniki genetyczne oraz różne aktywne biologicznie substancje wydzielane przez tkankę tłuszczową. Ze względu na powyższe zależności celowe wydaje się wykonywanie u chorych na łuszczycę badań przesiewowych w kierunku zaburzeń kardiometabolicznych, gdyż nie tylko zwiększają one śmiertelność u tych chorych, lecz także znacznie obniżają jakość ich życia. Bardzo istotna jest też edukacja i poprawa relacji lekarz-pacjent oraz wczesne wdrażanie profilaktyki.